Literature DB >> 17785546

Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative.

Alfredo A Molinolo1, Stephen M Hewitt, Panomwat Amornphimoltham, Somboon Keelawat, Samraeung Rangdaeng, Abelardo Meneses García, Ana R Raimondi, Rafael Jufe, María Itoiz, Yan Gao, Dhananjaya Saranath, George S Kaleebi, George H Yoo, Lee Leak, Ernest M Myers, Satoru Shintani, David Wong, H Davis Massey, W Andrew Yeudall, Fulvio Lonardo, John Ensley, J Silvio Gutkind.   

Abstract

PURPOSE: As an approach to evaluate the expression pattern and status of activation of signaling pathways in clinical specimens from head and neck squamous cell carcinoma (HNSCC) patients, we established the Head and Neck Cancer Tissue Array Initiative, an international consortium aimed at developing a high-density HNSCC tissue microarray, with a high representation of oral squamous cell carcinoma. EXPERIMENTAL
DESIGN: These tissue arrays were constructed by acquiring cylindrical biopsies from multiple individual tumor tissues and transferring them into tissue microarray blocks. From a total of 1,300 cases, 547 cores, including controls, were selected and used to build the array.
RESULTS: Emerging information by the use of phosphospecific antibodies detecting the activated state of signaling molecules indicates that the Akt-mammalian target of rapamycin (mTOR) pathway is frequently activated in HNSCC, but independently from the activation of epidermal growth factor receptor or the detection of mutant p53. Indeed, we identified a large group of tissue samples displaying active Akt and mTOR in the absence of epidermal growth factor receptor activation. Furthermore, we have also identified a small subgroup of patients in which the mTOR pathway is activated but not Akt, suggesting the existence of an Akt-independent signaling route stimulating mTOR.
CONCLUSIONS: These findings provide important information about the nature of the dysregulated signaling networks in HNSCC and may also provide the rationale for the future development of novel mechanism-based therapies for HNSCC patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785546     DOI: 10.1158/1078-0432.CCR-07-1041

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  100 in total

1.  mTOR as a molecular target in HPV-associated oral and cervical squamous carcinomas.

Authors:  Alfredo A Molinolo; Christina Marsh; Mohamed El Dinali; Nitin Gangane; Kaitlin Jennison; Stephen Hewitt; Vyomesh Patel; Tanguy Y Seiwert; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2012-03-12       Impact factor: 12.531

Review 2.  mTOR inhibitors and its role in the treatment of head and neck squamous cell carcinoma.

Authors:  Shaun A Nguyen; David Walker; M Boyd Gillespie; J Silvio Gutkind; Terry A Day
Journal:  Curr Treat Options Oncol       Date:  2012-03

3.  Whole genome expression profiling in chewing-tobacco-associated oral cancers: a pilot study.

Authors:  Sanjukta Chakrabarti; Shaleen Multani; Jyoti Dabholkar; Dhananjaya Saranath
Journal:  Med Oncol       Date:  2015-02-07       Impact factor: 3.064

4.  Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma.

Authors:  Marta Moral; Carmen Segrelles; M Fernanda Lara; Ana Belén Martínez-Cruz; Corina Lorz; Mirentxu Santos; Ramón García-Escudero; Jerry Lu; Kaoru Kiguchi; Agueda Buitrago; Clotilde Costa; Cristina Saiz; Jose L Rodriguez-Peralto; Francisco J Martinez-Tello; Maria Rodriguez-Pinilla; Montserrat Sanchez-Cespedes; Marina Garín; Teresa Grande; Ana Bravo; John DiGiovanni; Jesús M Paramio
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

5.  A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

Authors:  Julie E Bauman; Hugo Arias-Pulido; Sang-Joon Lee; M Houman Fekrazad; Hiroyuki Ozawa; Elana Fertig; Jason Howard; Justin Bishop; Hao Wang; Garth T Olson; Michael J Spafford; Dennie V Jones; Christine H Chung
Journal:  Oral Oncol       Date:  2013-02-04       Impact factor: 5.337

6.  Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions.

Authors:  Panomwat Amornphimoltham; Kantima Leelahavanichkul; Alfredo Molinolo; Vyomesh Patel; J Silvio Gutkind
Journal:  Clin Cancer Res       Date:  2008-12-10       Impact factor: 12.531

7.  Akt2 overexpression plays a critical role in the establishment of colorectal cancer metastasis.

Authors:  Piotr G Rychahou; JungHee Kang; Pat Gulhati; Hung Q Doan; L Andy Chen; Shu-Yuan Xiao; Dai H Chung; B Mark Evers
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-15       Impact factor: 11.205

8.  A role for p38 MAPK in head and neck cancer cell growth and tumor-induced angiogenesis and lymphangiogenesis.

Authors:  Kantima Leelahavanichkul; Panomwat Amornphimoltham; Alfredo A Molinolo; John R Basile; Sittichai Koontongkaew; J Silvio Gutkind
Journal:  Mol Oncol       Date:  2013-10-12       Impact factor: 6.603

9.  Hypoxia-induced energy stress inhibits the mTOR pathway by activating an AMPK/REDD1 signaling axis in head and neck squamous cell carcinoma.

Authors:  Abraham Schneider; Rania H Younis; J Silvio Gutkind
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

10.  Transgenic mice expressing constitutively active Akt in oral epithelium validate KLFA as a potential biomarker of head and neck squamous cell carcinoma.

Authors:  Marta Moral; Carmen Segrelles; Ana Belén Martínez-Cruz; Corina Lorz; Mirentxu Santos; Ramón García-Escudero; Jerry Lu; Agueda Buitrago; Clotilde Costa; Cristina Saiz; José M Ariza; Marta Dueñas; Jose L Rodriguez-Peralto; Francisco J Martinez-Tello; Maria Rodriguez-Pinilla; Montserrat Sanchez-Cespedes; John Digiovanni; Jesús M Paramio
Journal:  In Vivo       Date:  2009 Sep-Oct       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.